Antiulcer activity of 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole dinitrate in ethanol-prednisolone damage to gastric mucosa

Nowadays, the search for new effective and safe medicines for the treatment of acid-dependent gastrointestinal diseases remains an urgent problem of modern pharmacology.

The aim of this study was an experimentally study of the anti-ulcer activity of 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole dinitrate on the model of damage to the gastric mucosa caused by the administration of 80% ethanol and prednisolone combination (20 mg/kg).

Materials and methods. To simulate the damage to the gastric mucosa, the experimental animals (white male Wistar rats) were administrated with prednisone at the rate of 20 mg/kg and 80% ethyl alcohol at the dose of 0.6 ml/100 g of the animal body weight. Prednisolone was dissolved in 80% alcohol. Antisecretory antiulcer agents actively used in clinical practice, were selected as reference drugs: ranitidine (30 mg/kg, 10 mg/kg and 3 mg/kg) and omeprazole (3 mg/kg, 1 mg/kg and 0.3 mg/kg). The studied compound was used at the doses of 30 mg/kg, 10 mg/kg and 3 mg/kg. All the substances under study were administered intragastrically with the use of an atraumatic probe. 

Results. It has been established that the benzimidazole derivative in the studied doses contributes to a dose-dependent reliable reduction in the area and depth of ulcerative lesions of the gastric mucosae relative to the control and reference drugs (ranitidine and omeprazole). In addition, in the maximum studied dose (30 mg/kg), the proportion of the animals with ulcerative lesions significantly decreases by more than 2 times. The calculated ED50 values for the benzimidazole derivative and ranitidine were 5.09 mg/kg and 38.23 mg/kg, respectively.

Conclusion. The obtained experimental data indicate that the benzimidazole derivative has a pronounced dose-dependent antiulcer effect on the model of ethanol-prednisolone erosive-ulcerous defects of the rats’ gastric mucosae, which is superior to the effects of the reference preparations. It makes its further study promising.

1. Maev IV, Andreev DN, Zaborovsky AV. Basics of gastric acid secreti Medical Council. 2018;(3):7–14. Doi:htt s://doi.org/10.21518/2079-701X-2018-3-7-14. (in Russ)

2. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol. 2017;33(6):430–8. doi: 10.1097/MOG.0000000000000392.

3. Salahuddin A, Shaharyar M, Mazumder A. Benzimidazoles: A biologically active compounds. Arabian J Chem. 2017;10:157–73.

4. Hockley MH, Titman RB. Antiulcer benzimidazole derivatives. Patent US 4767769 A; No US 07/065,363; 30 Aug 1988. Available at: https://patents.google.com/patent/US4767769A/en

5. Spasov AA, Petrov VI, Anisimova VA, Minkin VI, Chernikov MV. Lekarstvennaya substantsiya dlya podavleniya gelikobakteropodobnykh erozivno-yazvennykh povrezhdeniy slizistoy obolochki zheludka [Drug substance for suppressing helicobacter-like erosive and ulcerative lesions of the gastric mucosa]. Patent RU 2395282 С2. Bul. No21; 2010. (in Russ)

6. Chernikov MV, Oganova MA, Gerasimenko AS, Artemyev EA. Antiulcer activity of dinitrate 2-phenyl-9diethylaminoethylamine[1,2-a]benzimidazole with helicobacter pylori-like damage of gastric mucosa. Pharmacy & Pharmacology. 2018;6(4):367–79. Doi: https://doi.org/10.19163/2307-9266-2018-6-4-367-379.

7. Chernikov MV, Oganova MA, Gerasimenko AS, Artemyev EA. Study of anti cretory acti of dinitrate 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole by method of conti perfusion of rats’ stomachs. Pharmacy & Pharmacology. 2019;7(4):231– 40. Doi: htt s://doi.org/10.19163/2307-9266-2019-7-4-231240.

8. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol. 2017;76(1):11–6.

9. Podvigina TT, Filaretova LP. Dvoystvennyye effekty glyukokorti oidnykh gormonov na slizistuyu obolochku zheludka [Dual Effects of Glucocorti oids on the Gastric Mucosa]. Advances in Physiological Sciences 2014;45(4):19–33. (in Russ)

10. Baginskaya AI, Ferubko EV, Kurmanova EN, Voskoboinikova IV, Kolkhir VK. Eksperimental’noye modelirovaniye v gastroenterologii. Prakti e rekomendatsii. Chast’ II. Eksperimental’nyye modeli «ostrykh» yazv zheludka [Experimental modelling in gastroenterology. Practi al guidelines. Part II. Experimental models of acute ulcer lesions of the stomach]. Problems of Biological, Medical and Pharmaceuti al Chemistry. 2016;3:32–40. (in Russ)

11. Simoes S, Lopes R, Campos MCD, Marruz MJ, da Cruz MEM, Corvo L. Animal models of acute gastric mucosal injury: Macroscopic and microscopic evaluation. Animal Model Exp Med. 2019;2:121–6.

12. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. Chast’ pervaya [Guidelines for preclinical studies of drugs. Part One]. Ed. A.N. Mironov, N.D. Bunatyan, A.N. Vasiliev et al. Мoscow, Grif & K; 2012: 944 p. (in Russ)

13. GOST R 33044–2014. Printsipy nadlezhashchey laboratornoy praktiki [Principles of Good Laboratory Practice]. (OECD Guide 1: 1998, IDT). Moscow, Standartinform; 2015:11 p. (in Russ)

14. Order of the Ministry of Health of the Russian Federation of April 1, 2016 N 199n “On the Approval of the Rules of Good Laboratory Practice” (Registered in the Ministry of Justice of the Russian Federation on August 15, 2016 N 43232). Bulletin of regulatory acts of federal executive bodies, N 37, 2016. (in Russ)

15. Adinortey MB, Ansah C, Galyuon I, Nyarko A. In vivo models used for evaluation of potential antigastroduodenal ulcer. Ulcers. 2013;2013:1–12. Doi: http://dx.doi.org/10.1155/2013/796405.

16. Viswanatha Swamy AHM, Sajjan M, Thippeswamy AHM, Koti BC, Sadiq AJ. Influence of Proton Pump Inhibitors on Dexamethasone-Induced Gastric Mucosal Damage in Rats. Indian J Pharm Sci. 2011;73(2):193–8. Doi: 10.4103/0250-474x.91582

17. Luo JC, Shin VY, Liu ES. et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol, 2004;485:275–81. Doi: 10.1016/j.ejphar.2003.11.038.

18. Luo JC, Chi CW, Lin HY. et al. Dexamethasone inhibits epidermal growth factor-stimulated gastric epithelial cell proliferation. J Pharmacol Exp Ther. 2007;320:687–94. DOI: 10.1124/jpet.106.113035

19. Zhou B, Li B, Yi W, et al. Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives. Bioorg Med Chem Lett. 2013;23(13):3759-63. doi: 10.1016/j.bmcl.2013.05.004.

20. Ates-Alagoz Z. Antioxidant activities of retinoidal benzimidazole or indole derivatives in In vitro model systems. Current Med. Chem. 2013; 20(36):4633–9. Doi: 10.1016/j.bmcl.2013.05.004

21. Gaba M, Singh S, Mohan C, et al. Design, Synthesis and Pharmacological Evaluation of Gastro-protective Anti-inflammatory Analgesic Agents based on Dual Oxidative Stress. Cyclooxygenase Inhibition. Antiinflamm Antiallergy Agents Med. Chem. 2019. Doi: 10.2174/1871523018666190325155244.